Zastosowanie gabapentyny w leczeniu bólu neuropatycznego – opis przypadków Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
mar 31, 2019
Słowa kluczowe:
ból neuropatyczny, neuropatie, farmakoterapia
##plugins.themes.bootstrap3.article.main##
Abstrakt
Ból neuropatyczny jest spowodowany uszkodzeniem obwodowego lub ośrodkowego układu nerwowego. Pojawia się w przebiegu licznych chorób, m.in. polineuropatii cukrzycowej lub polineuropatii o innej etiologii, neuralgii nerwu trójdzielnego, neuralgii popółpaścowej oraz zespołów korzeniowych. Typową cechą bólu neuropatycznego jest zła reakcja na standardowe leczenie przeciwbólowe. W jego leczeniu lekami pierwszego wyboru są leki przeciwpadaczkowe (gabapentyna i pregabalina, ewentualnie karbamazepina) oraz leki przeciwdepresyjne (amitryptylina i duloksetyna). W przypadku niedostateczej skuteczności powyższych leków można rozważyć dołączenie acetaminofenu lub opioidu, np. tramadolu. Niesteroidowe leki przeciwzapalne (NLPZ) nie są skuteczne w leczeniu bólu neuropatycznego [1, 2].
##plugins.themes.bootstrap3.article.details##
Jak cytować
Durka-Kęsy, M. A. (2019). Zastosowanie gabapentyny w leczeniu bólu neuropatycznego – opis przypadków . Medycyna Faktów , 12(1(42), 44-47. https://doi.org/10.24292/01.MF.0119.8
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Szczudlik A., Dobrogowski J., Wordliczek J. et al.: Diagnosis and management of neuropathic pain: review of literature and recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society – Part Two. Neurol. Neurochir. Pol. 2014; 48(6): 423-435. DOI: 10.1016/j.pjnns.2014.11.002.
2. Fornasari D.: Pharmacotherapy for Neuropathic Pain: A Review. Pain Ther. 2017; 6(supl. 1): S25-S33. DOI: 10.1007/s40122-017-0091-4.
3. Marais E., Klughauer N., Hofman F.: Calcium channel alpha (2) delta subunit structure and gabapentin binding. Mol. Pharmacol. 2001; 59: 1243-1248.
4. Qadeer M., Waqas M., Rashid M.J. et al.: Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. Asian Spine J. 2017; 11(1): 93-98. DOI: 10.4184/asj.2017.11.1.93.
5. Mangaiarkkarasi A., Rameshkannan S., Meher Ali R.: Effect of Gabapentin and Pregabalin in Rat Model of Taxol Induced Neuropathic Pain. J. Clin. Diagn. Res. 2015; 9(5): FF11-4.
6. Agarwal M.M., Elsi Sy M.: Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin? Neurourol. Urodyn. 2017; 36(8): 2028-2033. DOI: 10.1002/nau.23225.
7. Robertson K., Marshman L.A.G., Plummer D., Downs E.: Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial. JAMA Neurol. 2018. DOI: 10.1001/jamaneurol.2018.3077.
8. Handforth A., Treiman D.M.: Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia 1994; 35(5): 1032-1037.
9. Moore A., Derry S., Wiffen P.: Gabapentin for Chronic Neuropathic Pain. JAMA 2018; 319(8): 818-819. DOI: 10.1001/jama.2017.21547.
10. Zhang M., Gao C.X., Ma K.T. et al.: A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. Biomed. Res. Int. 2018; 2018: 7474207. DOI: 10.1155/2018/7474207.
11. Rudroju N., Bansal D., Talakokkula S.T. et al.: Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013; 16(6): E705-14. Erratum in: Pain Physician. 2014; 17(2): 203.
12. Sills G.: The mechanism of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 2006; 6: 108-113.
13. Frampton J.E., Foster R.H.: Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005; 65: 111-118.
14. Frampton J.E., Scott L.J.: Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs 2004; 64: 2813-2820.
15. Fleet J.L., Dixon S.N., Kuwornu P.J. et al.: Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population- based study. PLoS One 2018; 13(3): e0193134. DOI: 10.1371/journal.pone.0193134. eCollection 2018.
16. Megna J.L., Devitt P.J., Sauro M.D., Dewan M.J.: Gabapentin’s effect on agitation in severely and persistently mentally ill patients. Ann. Pharmacother. 2002; 36: 12-16.
17. Chiappini S., Schifano F.: A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‚Suspected Adverse Drug Reactions’ Database. CNS Drugs 2016; 30(7): 647-54. DOI: 10.1007/s40263-016-0359-y.
18. Wiffen P.J., Derry S., Bell R.F. et al.: Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 2017; 6: CD007938. DOI: 10.1002/14651858.CD007938.pub4.
2. Fornasari D.: Pharmacotherapy for Neuropathic Pain: A Review. Pain Ther. 2017; 6(supl. 1): S25-S33. DOI: 10.1007/s40122-017-0091-4.
3. Marais E., Klughauer N., Hofman F.: Calcium channel alpha (2) delta subunit structure and gabapentin binding. Mol. Pharmacol. 2001; 59: 1243-1248.
4. Qadeer M., Waqas M., Rashid M.J. et al.: Preventive Gabapentin versus Pregabalin to Decrease Postoperative Pain after Lumbar Microdiscectomy: A Randomized Controlled Trial. Asian Spine J. 2017; 11(1): 93-98. DOI: 10.4184/asj.2017.11.1.93.
5. Mangaiarkkarasi A., Rameshkannan S., Meher Ali R.: Effect of Gabapentin and Pregabalin in Rat Model of Taxol Induced Neuropathic Pain. J. Clin. Diagn. Res. 2015; 9(5): FF11-4.
6. Agarwal M.M., Elsi Sy M.: Gabapentenoids in pain management in urological chronic pelvic pain syndrome: Gabapentin or pregabalin? Neurourol. Urodyn. 2017; 36(8): 2028-2033. DOI: 10.1002/nau.23225.
7. Robertson K., Marshman L.A.G., Plummer D., Downs E.: Effect of Gabapentin vs Pregabalin on Pain Intensity in Adults With Chronic Sciatica: A Randomized Clinical Trial. JAMA Neurol. 2018. DOI: 10.1001/jamaneurol.2018.3077.
8. Handforth A., Treiman D.M.: Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia 1994; 35(5): 1032-1037.
9. Moore A., Derry S., Wiffen P.: Gabapentin for Chronic Neuropathic Pain. JAMA 2018; 319(8): 818-819. DOI: 10.1001/jama.2017.21547.
10. Zhang M., Gao C.X., Ma K.T. et al.: A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials. Biomed. Res. Int. 2018; 2018: 7474207. DOI: 10.1155/2018/7474207.
11. Rudroju N., Bansal D., Talakokkula S.T. et al.: Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician. 2013; 16(6): E705-14. Erratum in: Pain Physician. 2014; 17(2): 203.
12. Sills G.: The mechanism of action of gabapentin and pregabalin. Curr. Opin. Pharmacol. 2006; 6: 108-113.
13. Frampton J.E., Foster R.H.: Pregabalin: in the treatment of postherpetic neuralgia. Drugs 2005; 65: 111-118.
14. Frampton J.E., Scott L.J.: Pregabalin: in the treatment of painful diabetic peripheral neuropathy. Drugs 2004; 64: 2813-2820.
15. Fleet J.L., Dixon S.N., Kuwornu P.J. et al.: Gabapentin dose and the 30-day risk of altered mental status in older adults: A retrospective population- based study. PLoS One 2018; 13(3): e0193134. DOI: 10.1371/journal.pone.0193134. eCollection 2018.
16. Megna J.L., Devitt P.J., Sauro M.D., Dewan M.J.: Gabapentin’s effect on agitation in severely and persistently mentally ill patients. Ann. Pharmacother. 2002; 36: 12-16.
17. Chiappini S., Schifano F.: A Decade of Gabapentinoid Misuse: An Analysis of the European Medicines Agency’s ‚Suspected Adverse Drug Reactions’ Database. CNS Drugs 2016; 30(7): 647-54. DOI: 10.1007/s40263-016-0359-y.
18. Wiffen P.J., Derry S., Bell R.F. et al.: Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst. Rev. 2017; 6: CD007938. DOI: 10.1002/14651858.CD007938.pub4.